司美格鲁肽或预防青光眼？新适应症研究进展+1

Core Viewpoint - The use of GLP-1 receptor agonists significantly reduces the risk of glaucoma in diabetes patients, with a reduction of up to 50% compared to metformin [3][5]. Group 1: Research Findings - A large retrospective cohort study indicates that patients treated with GLP-1 receptor agonists like semaglutide show a 41-50% relative risk reduction for primary open-angle glaucoma (POAG) after 1-3 years of follow-up [5][10]. - The study highlights the neuroprotective effects of GLP-1 receptor agonists, including anti-inflammatory and antioxidant properties, which may contribute to lowering intraocular pressure [7][10]. - The research involved data from 120 healthcare organizations across 17 countries, utilizing propensity score matching to balance covariates such as demographics and comorbidities [8]. Group 2: Clinical Implications - The findings underscore the importance of incorporating GLP-1 receptor agonists into the clinical management of diabetes patients, as they provide additional benefits beyond glycemic control [7][10]. - The study's results suggest that GLP-1 receptor agonists, such as semaglutide (Ozempic) and liraglutide (Victoza), can offer glaucoma protection for type 2 diabetes patients [7][10]. Group 3: Regulatory Approvals - In January 2024, the oral formulation of semaglutide (Rybelsus) was approved in China for the treatment of type 2 diabetes, marking the first oral GLP-1 receptor agonist approved in the country [11]. - In June 2024, the National Medical Products Administration (NMPA) approved semaglutide injection (Wegovy) for long-term weight management in China, targeting patients with obesity or weight-related comorbidities [13][15]. - The approval of these innovative drugs is expected to provide effective weight management solutions and enhance the market potential for semaglutide globally [15].